4.6 Article

A longitudinal study of SLC6A4 DNA promoter methylation and poststroke depression

期刊

JOURNAL OF PSYCHIATRIC RESEARCH
卷 47, 期 9, 页码 1222-1227

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jpsychires.2013.04.010

关键词

Stroke; Depression; SLC6A4; DNA methylation; Genetic association study

资金

  1. Basic Science Research Program through the National Research Foundation of Korea (NRF)
  2. Ministry of Education, Science and Technology [2009-0087344]
  3. Korean Health Technology R&D Project Ministry of Health & Welfare, Republic of Korea [A120004]
  4. National Institute for Health Research (NIHR) Biomedical Research Centre and Dementia Biomedical Research Unit at South London and Maudsley NHS Foundation Trust
  5. King's College London

向作者/读者索取更多资源

Serotonin transporter gene (SLC6A4) has been shown to play an important role in the pathophysiology of mood disorders including poststroke depression (PSD). SLC6A4 expression is influenced by DNA methylation status and the SLC6A4 linked promoter region (5-HTTLPR) polymorphism. This study aimed to investigate whether SLC6A4 methylation status was associated with depression ascertained at two weeks and one year after stroke taking into account the 5-HTTLPR polymorphism. A total of 286 patients were evaluated two weeks after stroke, and 222 (78%) were followed one year later. Depression was diagnosed according to DSM-IV criteria, and depression severity was assessed by the Hamilton Depression Rating Scale (HAMD) at each evaluation point. The effects of SLC6A4 methylation status on PSD status and HAMD scores were investigated using multivariate logistic regression models and partial correlation tests, respectively. Analyses were repeated after stratification by 5-HTTLPR genotype groups ('l/l or l/s' and 's/s'). Higher SLC6A4 promoter methylation status was independently associated with PSD both at 2 weeks and more prominently at 1 year after stroke, and was significantly associated with the worsening of depressive symptoms over one year. These findings were significant only in the presence of the 5-HTTLPR s/s genotype. SLC6A4 methylation profile was supported as a potential diagnostic and prognostic biomarker for PSD; associations with SLC6A4 methylation status may represent a target for drug development. (C) 2013 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据